Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565144 | 0.83 | TDP1 (0.35) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL10623223 | 0.82 | PTGS2 (0.38) | PTGS2SLC6A4CYP1A2HPGDHSD17B10 | |
| SCHEMBL435264 | 0.81 | CYP1A2 (0.42) | PTGS2SLC6A4SLC6A3CYP1A2PTGS1 | |
| SCHEMBL695988 | 0.81 | PDCD1 (0.39) | PTGS2SLC6A4NPC1RAB9AHPGD | |
| SCHEMBL2014605 | 0.80 | PTGS2 (0.42) | PTGS2SLC6A4SLC6A3PTGS1TGFBR1 | |
| SCHEMBL7459931 | 0.80 | ALDH1A1 (0.39) | NPC1RAB9AHSD17B10MEN1KMT2A | |
| SCHEMBL8524724 | 0.79 | AHR (0.47) | CYP1A2NPC1RAB9AHSD17B10SMN1; SMN2 | |
| SCHEMBL20956991 | 0.79 | ESR2 (0.42) | CYP1A2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22115865 | 0.78 | — | — | |
| SCHEMBL4653269 | 0.78 | CYP1A2 (0.39) | PTGS2SLC6A4SLC6A3CYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016142486-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANTI-ANGIOGENIC RESISTANT CANCER | INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) (ES) | 2016-09-15 | — | — | WO | disclosed |
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | PTGS2 3400/4885SLC6A4 1673/4885SLC6A3 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.